Efficacy of Erenumab on Functional Impact of Migraine
Public ClinicalTrials.gov record NCT04465357. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open Label Study Assessing the Efficacy of Erenumab on Functional Impact of Migraine
Study identification
- NCT ID
- NCT04465357
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Merle Diamond
- Other
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Interventions
- Erenumab-Aooe 140 MG/ML [Aimovig] Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 2020
- Primary completion
- Jun 2, 2022
- Completion
- Jun 2, 2022
- Last update posted
- Oct 4, 2022
2020 – 2022
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Diamond Headache Clinic | Chicago | Illinois | 60642 | — |
| StudyMetrix | City of Saint Peters | Missouri | 63303 | — |
| Clinvest Research | Springfield | Missouri | 65810 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04465357, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 4, 2022 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04465357 live on ClinicalTrials.gov.